Expert consensus statement on Diemailing~® Kudiezi Injection in clinical practice.
10.19540/j.cnki.cjcmm.20190509.502
- Author:
Xing LIAO
1
;
Yun-Ling ZHANG
2
;
Yan-Ming XIE
1
;
Da-Zhuo SHI
2
;
Su-Lun SUN
3
;
Yi-Huai ZOU
3
;
Jun LI
4
;
Wei-Xing LU
5
;
Mei JIN
6
;
Hong-Xu LIU
6
;
Xue-Chun TANG
3
;
Xiang-Lan JIN
7
;
Yun-Zhi MA
8
;
Si-Yan ZHAN
9
;
Jian-Ping LIU
10
;
Yao-Long CHEN
11
Author Information
1. Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences Beijing 100700,China.
2. Xiyuan Hospital,China Academy of Chinese Medical Sciences Beijing 100091,China.
3. Dongzhimen Hospital,Beijing University of Chinese Medicine Beijing 100700,China.
4. Guang'anmen Hospital,China Academy of Chinese Medical Sciences Beijing 100053,China.
5. the Third Affiliated Hospital of Beijing University of Chinese Medicine Beijing 100029,China.
6. Beijing Hospital of Traditional Chinese Medicine,Capital Medical University Beijing 100010,China.
7. Dongfang Hospital,Beijing University of Chinese Medicine Beijing 100078,China.
8. the First Affiliated Hospital of Henan University of Traditional Chinese Medicine Zhengzhou 450000,China.
9. Evidence-Based Medicine Center of Peking University Beijing 100191,China.
10. Evidence-Based Medicine Center of Beijing University of Chinese Medicine Beijing 100900,China.
11. Evidence-Based Medicine Center of Lanzhou University Lanzhou 730000,China.
- Publication Type:Journal Article
- Keywords:
GRADE;
Kudiezi Injection;
expert consensus;
recommendation
- MeSH:
Angina Pectoris;
drug therapy;
Cerebral Infarction;
drug therapy;
China;
Consensus;
Coronary Disease;
drug therapy;
Drugs, Chinese Herbal;
therapeutic use;
Humans;
Injections;
Medicine, Chinese Traditional
- From:
China Journal of Chinese Materia Medica
2019;44(14):2926-2931
- CountryChina
- Language:Chinese
-
Abstract:
Diemailing~® Kudiezi Injection( DKI) is widely used in the treatment of cerebral infarction,coronary heart disease and angina pectoris. Long-term clinical application and related research evidence showed that DKI has a good effect in improving the clinical symptoms of cardiovascular and cerebrovascular diseases. However,this injection has not been included in any clinical practice guideline. It has been found that the use of DKI is in wrong way in clinical practice in recent years. Therefore,clinical experts from the field of cardiovascular and cerebrovascular diseases nationwide are invited to compile this expert consensus in order to guide clinicians.GRADE system is used to grade the quality of evidence according to different outcomes according to degrading factors. Then it forms the recommendation or consensus suggestion through the nominal group method. The formation of expert consensus mainly considers six factors: quality of evidence,economy,efficacy,adverse reactions,patient acceptability and others. Based on these six aspects,if the evidence is sufficient,a " recommendation" supported by evidence is formed,and GRADE grid voting rule is adopted. If the evidence is insufficient,a " consensus suggestions" will be formed,using the majority voting rule. In this consensus,the clinical indications,efficacy,safety evidences and related preliminary data of DKI were systematically and comprehensively summarized in a concise and clear format,which could provide valuable reference for the clinical use of DKI. This consensus has been approved by China association of Chinese medicine which is numbered GS/CACM 202-2019.
